Green Cross Medical Science Corporation - Asset Resilience Ratio
Green Cross Medical Science Corporation (142280) has an Asset Resilience Ratio of 9.78% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check 142280 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Green Cross Medical Science Corporation's Asset Resilience Ratio has changed over time. See 142280 net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Green Cross Medical Science Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 142280 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩9.41 Billion | 9.78% |
| Short-term Investments | ₩0.00 | 0% |
| Total Liquid Assets | ₩9.41 Billion | 9.78% |
Asset Resilience Insights
- Limited Liquidity: Green Cross Medical Science Corporation maintains only 9.78% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Green Cross Medical Science Corporation Industry Peers by Asset Resilience Ratio
Compare Green Cross Medical Science Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Green Cross Medical Science Corporation (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Green Cross Medical Science Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | ₩0.00 ≈ $0.00 |
₩90.53 Billion ≈ $61.35 Million |
-- |
| 2022-12-31 | 11.14% | ₩10.75 Billion ≈ $7.28 Million |
₩96.47 Billion ≈ $65.38 Million |
+9.22pp |
| 2021-12-31 | 1.92% | ₩1.84 Billion ≈ $1.25 Million |
₩95.63 Billion ≈ $64.81 Million |
-2.34pp |
| 2020-12-31 | 4.26% | ₩4.50 Billion ≈ $3.05 Million |
₩105.60 Billion ≈ $71.57 Million |
-11.14pp |
| 2019-12-31 | 15.40% | ₩13.68 Billion ≈ $9.27 Million |
₩88.87 Billion ≈ $60.22 Million |
+1.40pp |
| 2018-12-31 | 13.99% | ₩8.95 Billion ≈ $6.07 Million |
₩63.97 Billion ≈ $43.35 Million |
+8.04pp |
| 2017-12-31 | 5.95% | ₩3.60 Billion ≈ $2.44 Million |
₩60.54 Billion ≈ $41.03 Million |
+2.10pp |
| 2016-12-31 | 3.85% | ₩2.45 Billion ≈ $1.66 Million |
₩63.61 Billion ≈ $43.10 Million |
-- |
About Green Cross Medical Science Corporation
GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company's products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CER… Read more